Barbora De Courten (Associate Professor at Monash University, Melbourne, Australia) discusses the latest studies into carnosine supplementation in diabetes prevention at ADA 2018. Carnosine is food supplement and has been shown in animal studies to prevent and be useful in the treatment of type 2 diabetes. It has been show to have anti-inflammatory, anti-oxidative, and anti-advanced glycation end product properties that are important mechanisms in type 2 diabetes and related diseases. The study presented at this meeting showed the effect of carnosine supplementation on cardiometabolic risk factors in obesity, prediabetes and diabetes.
1. What is carnosine? (0:14)
2. What is the rationale behind its use in the prevention of diabetes? (0:35)
3. What are the key findings of your study around the effect of carnosine supplementation on cardiometabolic risk factors in obesity, prediabetes and diabetes? (1:21)
4. What are the key challenges in preventing diabetes? (1:49)
Filmed at ADA 2018, Orlando, FL, US
Share this Video
Related Videos In Diabetes
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!